Crucial US Advisory Committee to Decide on Modifying Infant Hepatitis B Vaccine Guideline
Following a postponement and an unusually contentious session, a government vaccine expert group was scheduled to decide on Friday concerning altering the long-held guideline that all newborns be inoculated against hepatitis B.
Intense Discussion and a Postponed Decision
The opening session of the conference on Thursday was marked by intense argument over limiting availability to the hepatitis B vaccine for newborns and a choice to postpone the decision by a day to provide committee members extra time to review the wording. The committee, which advises the Centers for Disease Control and Prevention on vaccine use, had twice before postponed.
“Is there any concrete proof of injury of giving this immunization before 30 days? Or is this theory?” questioned one panel member.
In answer, another member stated, “There is limited evidence about the long-term risk.”
Present Protocol and Potential Impact
The shot is currently suggested for each baby within 24 hours of being born to prevent infection of hepatitis B, which can cause significant hepatic injury. It has been provided to more than a billion persons for more than three decades.
The Atlanta conference presented no recent proof of damage attributable to the vaccine. Specialists note any change to the existing hepatitis B vaccination schedule could have major and extensive repercussions for childhood health in the United States.
Panel Composition and Latest Shifts
The advisory panel can only make recommendations to the head of the CDC. The committee's composition has seen shifts recently, with the declaration that the committee’s most recent chair would depart for an agency job and be substituted with a cardiac doctor who has been questioning of other inoculations.
The board includes multiple immunization doubters who are in agreement with a goal to reform – and potentially, in some cases, scrap – longstanding immunization guidelines.
